Thomas Hannaford consults for PF2 on complex litigation matters, bringing his experience as an equities analyst to cases concerning equity valuations, issues at the time of a merger, IPO or other fund-raisings, market norms, and evaluating the "but-for" when disclosure is alleged to have been improper or incomplete. Tom has been engaged both as a testifying expert and a litigation strategist. He has held consultant equity analyst roles at Acova Capital, Patersons Securities (now known as Canaccord Financial Group), and TBF Investment Management. He has also held several advisory positions - including corporate strategy and M&A advisory - at biotech companies and in the energy/metals/minerals sectors, including with Calzada Ltd (now known as Polynovo Ltd), Xerion Ltd, Cancure Ltd, Valence Industries Ltd, EnGeneic Ltd and Geodynamics Ltd. With his biotech background, Tom has expertise in the analysis of clinical trial results provided in discovery, medical device or drug development analyses, or related market or competitive market dynamics analyses. Tom holds a First Class Honours degree in Architectural Studies from the University of Adelaide and a Master's degree in Philosophy from the University of Warwick. He was a Doctor of Philosophy (D.Phil.) candidate in Philosophy at Oxford University. He also lectured in Philosophy at Magdalen College, Oxford University.
"I worked closely with Thomas in a complex securities class action concerning a prominent medical research and development company. His insights were invaluable throughout the case and his depth of knowledge in the field of medical research and product development is highly impressive."
— Guy Donnellan, Barrister, Level 22 Chambers, Sydney